Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
Gallegos Ruiz, Marielle
Le Chevalier, Thierry
Rodriguez, Jose Antonio
AffiliationDepartment of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, the Netherlands. firstname.lastname@example.org
MetadataShow full item record
AbstractPURPOSE: Erlotinib has proven activity in pretreated patients with advanced non-small cell lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC and assessed biological predictors of outcome. EXPERIMENTAL DESIGN: In this phase II study, chemotherapy-naive patients with stage IIIB/IV NSCLC received oral erlotinib (150 mg/d) until disease progression or unacceptable toxicity occurred. Tumor response was assessed every 6 weeks, and samples were analyzed for potential molecular markers of treatment response and survival. The primary end point was the proportion of patients without disease progression after 6 weeks of treatment. RESULTS: Fifty-three patients were eligible. The overall rate of nonprogression at 6 weeks was 52.8% (28 of 53 patients). Tumor response rate was 22.7%, with 1 complete response, 11 partial responses, and 16 cases of stable disease. Responses were seen across most patient clinical characteristics. The median duration of tumor response was 333 days; median overall survival was 391 days; and median time to disease progression was 84 days. Erlotinib was well tolerated, the main treatment-related adverse events being mild-to-moderate rash and diarrhea. Histologic material for biological studies was available in 29 cases. Four of five responders and one patient with stable disease had a classic epidermal growth factor receptor tyrosine kinase mutation. Two progressing patients exhibited epidermal growth factor receptor point mutations (one with T790M mutation), and K-ras mutations were detected in 10 nonresponders. CONCLUSIONS: Erlotinib shows significant antitumor activity in the first-line treatment of advanced NSCLC and may be a viable alternative to chemotherapy. Patient selection cannot easily be based on clinical or biological variables.
CitationErlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. 2006, 12 (20 Pt 1):6049-55 Clin. Cancer Res.
JournalClinical Cancer Research
- Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
- Authors: Horiike A, Yamamoto N, Tanaka H, Yanagitani N, Kudo K, Ohyanagi F, Ono A, Naito T, Murakami H, Horai T, Nishio M
- Issue date: 2014 Apr
- Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
- Authors: Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H, Kim JH
- Issue date: 2007 Jun 20
- Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
- Authors: Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ
- Issue date: 2012 Jan
- Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
- Authors: Farina G, Longo F, Martelli O, Pavese I, Mancuso A, Moscetti L, Labianca R, Bertolini A, Cortesi E, Farris A, Fagnani D, Locatelli MC, Valmadre G, Ardizzoia A, Tomirotti M, Rulli E, Garassino MC, Scanni A
- Issue date: 2011 Mar
- Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
- Authors: Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL, Taron M
- Issue date: 2011 Mar 1